Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell

See also
Status	Clinical Trial	Phase
Completed	`NCT02546440` - Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)	Phase 2
Recruiting	`NCT04014374` - Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Active, not recruiting	`NCT01460914` - Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Completed	`NCT04955340` - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat	Phase 1
Recruiting	`NCT02539472` - Early Diagnosis of Mycosis Fungoides	N/A
Recruiting	`NCT05680558` - Photopheresis in Early-stage Mycosis Fungoides	Phase 2
Recruiting	`NCT01132989` - Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma	Phase 2
Recruiting	`NCT05414500` - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides	Phase 1
Terminated	`NCT01663571` - STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
Active, not recruiting	`NCT02192021` - Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)	Phase 1
Recruiting	`NCT05781386` - A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors	Phase 1
Active, not recruiting	`NCT02576496` - Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT03775525` - Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer	Phase 1
Active, not recruiting	`NCT01396070` - Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level	N/A
Completed	`NCT01198665` - RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas	Phase 1/Phase 2
Recruiting	`NCT03932279` - Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Not yet recruiting	`NCT05728879` - Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution	Early Phase 1
Not yet recruiting	`NCT06113081` - Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Completed	`NCT01569724` - Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma	Phase 4

NCT number	NCT03235869
Study type	Interventional
Source	University of Michigan Cancer Center
Contact
Status	Withdrawn
Phase	Early Phase 1
Start date	March 1, 2018
Completion date	March 1, 2023

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms